QIAGEN Reports Preliminary Q3 2019 Results and Announces Measures to Prioritize Resource Allocation

  • Preliminary Q3 2019 sales of about 3% CER growth (vs.~4-5% CER outlook), adjusted EPS in line with outlook
  • Initiatives announced to free up resources to invest in best growth opportunities, in particular new partnership with Illumina in NGS clinical decision-making

VENLO, Netherlands–(BUSINESS WIRE)–$QGEN–QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary sales results for the third quarter of 2019 and measures to prioritize resource allocation to the most attractive growth opportunities in its Sample to Insight portfolio, in particular in light of a new orientation for its next-generation sequencing (NGS) activities.

For the third quarter of 2019, QIAGEN currently expects preliminary total net sales growth of about 3% at constant exchange rates (CER) compared to the outlook for about 4-5% CER growth, and mainly due to significantly weaker-than-expected developments in China. Total sales growth was about 6% CER excluding China sales. QIAGEN anticipates adjusted EPS within its outlook for approximately $0.35-0.36 CER. Further information will be provided when QIAGEN plans to report results for the third quarter and first nine months of 2019 on October 30, 2019.

The measures to free up resources comes as QIAGEN announced a new strategic collaboration with Illumina Inc. to advance the use of NGS technologies in clinical decision-making. As a result, QIAGEN has established a new orientation for its NGS-related activities that involves focusing development activities on this collaboration as well as expanding its offering of universal NGS consumables solutions for use with any sequencer. QIAGEN intends to continue supporting customers of the GeneReader NGS System, which is a complete Sample to Insight system for the processing of smaller targeted gene panels, but has now decided to suspend ongoing NGS-related instrument development activities .

Please find the full press release here


John Gilardi

Vice President Corporate Communications and Investor Relations

+49 2103 29 11711 and +1 240 686 2222


Phoebe Loh

Associate Director Investor Relations

+49 2103 29 11457


Dr. Thomas Theuringer

Senior Director Public Relations and Digital Communications

+49 2103 29 11826 and +1 240 686 7425



Thank you for donating to DutchNews.nl.

We could not provide the Dutch News service, and keep it free of charge, without the generous support of our readers. Your donations allow us to report on issues you tell us matter, and provide you with a summary of the most important Dutch news each day.

Make a donation